查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1198082

臨床前成像市場 - 增長、趨勢、COVID-19 影響和預測 (2023-2028)

Preclinical Imaging Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 112 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

在預測期內（2022 年至 2027 年），臨床前成像市場預計將以近 6.00% 的複合年增長率增長。

當前 2019 冠狀病毒病 (COVID-19) 危機正在加深，臨床實踐正在發生重大變化。 根據 2020 年發表的論文“當前的冠狀病毒病 2019 (COVID-19) 危機持續增長並導致臨床操作發生顯著變化”，學術醫療機構和大學在臨床準備的同時，我們已經緊急停止了科學研究活動，以最大限度地保持社交距離，並最大限度地減少感染對研究人員和潛在接觸者的傳播。 放射學領域的研究人員一直在努力解決這些繼續影響當前和未來成像研究的問題。

但是，由於旅行限制和改進的健康預防措施，一些製造商已經恢復運營。 例如，Euro-BioImaging Node 現在根據 COVID-19 設置為外部用戶提供服務。 此外，Euro-BioImaging 通過圖像數據交換支持與 COVID-19 相關的研究活動，例如大型藥物篩選項目。 該公司與協作研究基礎設施 EU-OPENSCREEN 合作。 EU-OPENSCREEN 使用人體細胞和 SARS-CoV-2 分離株測試了 5,632 種化學物質抑制病毒引起的細胞毒性的能力，以確定針對 SARS-CoV-2 的臨床試驗候選物。 預計這將增加 COVID-19 大流行期間對臨床前成像的需求。

2020 年 3 月，MILabs 還宣布了用於 COVID-19 動物模型體內成像的臨床前診斷 U-CT，以便在預期抗病毒研究工具需求增加的情況下測試冠狀病毒疫苗和藥物。改進設備。 超高分辨率非侵入性肺部成像使研究人員能夠精確定位小鼠、豚鼠和雪貂支氣管中疾病過程的位置。 此外，對於與呼吸系統綜合症相關的冠狀病毒基因型的高通量篩選，可以使用本徵低溫框架肺部成像並同時掃描多達四個小鼠模型。

導致臨床前成像市場增長的關鍵因素包括分子成像技術的進步、對非侵入性小動物成像技術的需求增加以及私人和公共機構對臨床前研究的資金增加。

分子成像是一種快速發展的跨學科技術，包括分子生物學、化學、計算、工程學和醫學。 分子成像能夠在細胞或分子水平上對體內生理和病理過程進行非侵入性實時可視化和測量。

多模態分子影像增強了臨床醫生在篩查、監測、分期、預後預測、治療計劃與指導、療效監測、復發評估等方面的能力，在多種疾病的臨床治療中具有重要的作用。

此外，多模態分子影像技術的使用具有實現預後檢測、靶向治療和個性化醫療的潛力，技術進步顯著。 Aspect Imaging 與 Aspect 的 M2 平台和產品套件一起，使研究人員能夠利用 MRI 的強大功能和定量洞察力進行小動物表型分析和藥物開發，但成本和傳統 MRI 系統的複雜性沒有技術負擔。

臨床前成像市場趨勢

微超聲是醫療器械領域增長最快的市場

顯微超聲是超聲波的微型化版本，有望有更廣泛的應用，尤其是在小動物模型相關的研究中。 這種診斷成像技術的微型化版本增強了該技術的有效性。 根據 2020 年 5 月發表的題為“臨床前超聲成像 - 技術和成像應用綜述”的研究，超聲成像是一種臨床工具，可提供實時和定量的人體解剖學和生理學信息。建立為一種圖像技術。

此外，它還可以減少給定研究所需的動物數量。 在過去十年中，臨床前成像已成為推進生物醫學發現的重要工具。 高頻微超聲在後基因組時代穩步發展，成為一種快速且相對便宜的成像工具，用於研究使用小動物的正常發育和人類疾病模型。 這一發展的基本障礙之一是與高頻陣列換能器相關的技術障礙。

產品發布也是市場增長的因素之一。 例如，2020 年 10 月，福克斯蔡斯癌症中心推出了一種新的顯微超聲系統，醫生稱該系統可能會改變前列腺癌的診斷和治療方式。 預計此類批准將促進市場增長。

研究了臨床前顯微超聲在發育生物學、癌症和心血管疾病中的應用。 未來還會有高頻超聲成像的最新進展。 在臨床前研究中結合多種成像方式，使研究人員能夠了解活體動物的分子、細胞和生理變化，並預測患者新療法的結果。 因此，由於上述因素，預計市場在預測期內將出現高速增長。

臨床前成像市場預計將由北美主導

由於其發達的基礎設施、大量的臨床前項目以及對先進技術設備的廣泛採用，預計北美將主導臨床前成像市場。

COVID-19 大流行及其後果對美國的學術研究產生了重大影響。 2019 年冠狀病毒病 (COVID-19) 已經摧毀了世界，造成數億人死亡、經濟停擺、邊境關閉並在全球範圍內蔓延苦難。 由於距離和傳播問題，大多數非 COVID 臨床研究已停止。 當 SARS-CoV-2 在 2019 年底出現時，沒有獲得許可的藥物或疫苗。 當前的傳統藥物研發模式從開始到結束需要數年時間，但在這場危機中迫切需要採取行動，因此受到了挑戰。 抗病毒藥、免疫調節劑和抗凝血劑等藥物已經加速了可以作為“路線圖”的途徑，以幫助優先考慮用於臨床試驗的化合物。

因此，2020 年 4 月，美國國立衛生研究院 (NIH) 啟動了加速宣布 COVID-19 治療干預和疫苗 (ACTIV) 公私合作夥伴關係。

我們還知道，美國憑藉其完善的基礎設施以及大型公共和私營公司的存在而主導著市場。 不斷增加的研發資金加上高度發達的研究基礎設施正在加速美國臨床前成像市場的增長。

此外，越來越多的臨床研究組織 (CRO) 和製藥公司在臨床前研究中越來越多地採用體內成像系統，進一步加速了該市場的增長。

此外，公司正在提供新產品以實現產品組合的多樣化。 例如，2022 年 3 月，布魯克宣布推出 Ultima Investigator Plus，這是其行業領先的 Ultima 系列多光子顯微鏡的更新模塊化平台，用於深層組織熒光成像。 Investigator Plus 具有擴展的視野、優化的 2 光子和 3 光子成像光學器件以及增加的近距離耦合收集路徑，使研究人員能夠更深入地觀察要求苛刻的標本。 此外，每家公司都在開發新產品以擴大其產品組合。 例如，布魯克透露將於 2022 年 3 月推出 Ultima Investigator Plus。 它是行業領先的 Ultima 系列多光子顯微鏡用於深層組織熒光成像的最新靈活平台。 研究人員認為，擴大的視野、針對雙光子和三光子成像優化的光學器件以及擴展的緊耦合收集路徑將使科學家能夠在標本內部深處成像並看到更多。

因此，所有這些因素都有助於該地區的市場增長。

臨床前成像市場競爭對手分析

臨床前成像市場是一個適度整合的市場，參與者有大有小。 一些市場參與者是 Aspect Imaging Corporation、Bruker Corporation、Fujifilm Holdings Corporation、Li-Cor Biosciences、Mediso Ltd、Milabs BV、MR Solutions Ltd、PerkinElmer Corporation、Euro Bioimaging Eric、Trifoil Imaging、United Imaging Healthcare、Photon 等，AXT PTY LTD、Advanced Molecular Vision, Inc、IVIM Technology Corp.等 玩家正在採取各種策略，例如新產品發布和收購，以保持競爭力。

其他好處

  • Excel 格式的市場預測 (ME) 表
  • 三個月的分析師支持

內容

第1章介紹

  • 研究假設和市場定義
  • 調查範圍

第2章研究方法論

第 3 章執行摘要

第4章市場動態

  • 市場概覽
  • 市場驅動因素
    • 分子成像技術進步
    • 對非侵入性小動物成像技術的需求不斷增加
    • 私人和公共機構對臨床前研究的資助增加
  • 市場製約因素
    • 臨床前研究的嚴格規定
    • 與臨床前成像模式相關的高昂引進和運營成本
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分（基於價值的市場規模：100 萬美元）

  • 按方式
    • 光學成像設備
    • 核醫學成像系統
    • 顯微核磁共振成像
    • 微超聲
    • 顯微CT
    • 光聲成像裝置
    • 其他方式
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東
      • 海灣合作委員會
      • 南非
      • 其他中東地區
    • 南美洲
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章競爭格局

  • 公司簡介
    • Aspect Imaging Ltd
    • Bruker Corporation
    • Fujifilm Holdings Corporation
    • Mediso Ltd
    • MR Solutions Ltd
    • PerkinElmer Inc.
    • Trifoil Imaging
    • Euro-BioImaging ERIC
    • United Imaging Healthcare Co. Ltd
    • Photon etc.
    • AXT PTY LTD
    • Advanced Molecular Vision, Inc.
    • IVIM Technology Corp.

第7章 市場機會與今後動向

簡介目錄
Product Code: 47303

The preclinical imaging market is expected to register a CAGR of nearly 6.00% during the forecast period (2022-2027).

The current coronavirus disease 2019 (COVID-19) crisis has worsened, and clinical operations have changed dramatically. According to the article "The Current Coronavirus Disease 2019 (COVID-19) Crisis Continues to Grow and Has Resulted in Marked changes to clinical operations," published in 2020, academic medical centers and universities have rushed to shut down scientific research activities to maximize social distancing and minimize the spread of infection to research staff and others with whom they might come into contact, in parallel with clinical preparedness. Researchers in the field of radiology were wrestling with these issues, which will continue to affect present and future imaging studies.

However, with travel restrictions and improved sanitary precautions in place, Several manufacturers have resumed operations. Euro-BioImaging Nodes, for example, are tailored to the COVID-19 setting to give services to external users. Furthermore, Euro-BioImaging is assisting COVID-19-related research efforts, such as major drug screening projects, with picture data exchange. The company is collaborating with EU-OPENSCREEN, a partner research infrastructure. Using human cells and a SARS-CoV-2 isolate, EU-OPENSCREEN tested 5,632 chemicals for their ability to suppress viral-induced cytotoxicity to identify potential candidates for clinical trials against SARS-CoV-2. This is expected to boost the demand for preclinical imaging during the COVID-19 pandemic.

Also, in March 2020, MILabs improved their preclinical diagnostic U-CT system for in-vivo imaging of COVID-19 animal models in anticipation of rising demand for antiviral research tools and to enable the testing of coronavirus vaccines and medications. Ultra-high-resolution non-invasive lung imaging is one of the new features, allowing researchers to pinpoint the exact location of diseased processes in the bronchi of mice, guinea pigs, and ferrets. Furthermore, employing intrinsic freeze-frame lung imaging, up to four mice models can be scanned simultaneously for high-throughput screening of respiratory syndrome-associated coronavirus genotypes.

The major factors leading to the growth of the preclinical imaging market include the technological advancements in molecular imaging, increasing demand for non-invasive small animal imaging techniques, and an increase in preclinical research funding, by both private and public organizations.

Molecular imaging is a rapidly developing multidiscipline, which involves molecular biology, chemistry, computer, engineering, and medicine. It can recognize non-invasive and real-time visualization and measurement of the physiological or pathological process in the living organism at the cellular or molecular level.

Multimodal molecular imaging can play important role in the clinical care of various diseases by improving clinicians' ability to perform screening, surveillance, staging, prognosis, planning and therapy guidance, monitoring therapy efficacy, and assessing recurrence.

With its rapid technological advances, presymptomatic detection, targeted therapy, and personalized medicine may be possible shortly through the use of multimodal molecular imaging. Aspect imaging developed Aspect's M2 platform and the suite of products enable researchers to harness the power and quantitative insights of MRI for small animal phenotyping and drug development but without the cost, complexity, and technical burden of traditional MRI systems.

Preclinical Imaging Market Trends

Micro-Ultrasound is the Segment by Modality and is Expected to be the Fastest Growing Market

Micro-ultrasound is a miniature version of ultrasound that has a wider range of applications, especially in research related to small animal models. These smaller versions of imaging techniques boost the efficacy of the techniques. As per the study published in May 2020 titled 'Preclinical Ultrasound Imaging-A Review of Techniques and Imaging Applications', ultrasound imaging is a well-established clinical imaging technique providing real-time, quantitative anatomical and physiological information in humans.

Additionally, they reduce the number of animals required for a particular study. Over the past decade, preclinical imaging has emerged as an important tool to facilitate biomedical discovery. The high-frequency micro-ultrasound steadily evolved in the post-genomic era as a rapid, comparatively inexpensive imaging tool for studying normal development, and models of human disease in small animals. One of the fundamental barriers to this development was the technological hurdle associated with high-frequency array transducers.

Product launches are another factor in the growth of the market. For instance, in October 2020, Fox Chase Cancer Center has unveiled a new micro-ultrasound system that physicians say could change the way prostate cancer is diagnosed and treated. Such approvals are expected to boost market growth.

The applications of preclinical micro-ultrasound are explored for developmental biology, cancer, and cardiovascular disease. Concerning the future, the latest developments in high-frequency ultrasound imaging are also being developed. The combination of multiple imaging modalities in preclinical studies will help the researchers to understand the molecular, cellular, and physiological changes in living animals and to predict the outcome of new treatments in patients. Thus, owing to the all above-mentioned factors the market is expected to witness high growth over the forecast period.

North America is Expected to Dominate the Preclinical Imaging Market

North America is expected to dominate the preclinical imaging market because the region has a developed infrastructure, a large number of preclinical projects, and higher adoption rates of technically advanced devices in the region.

The COVID-19 pandemic and its aftermath have had a significant impact on academic studies in the United States. Coronavirus disease 2019 (COVID-19) has ravaged the globe, killing hundreds of millions of people, shutting down economies, closing borders, and spreading misery on a global scale. Most non-COVID clinical research has been halted due to distance and transmission concerns. There were no licensed medicines or vaccinations available when SARS-CoV-2 appeared at the end of 2019. The present paradigm of traditional drug research and development, which takes years from start to finish, is being challenged by the urgent need for countermeasures during this crisis. Antivirals, immunomodulators, anticoagulants, and other medicines have accelerated pathways that can be used as "roadmaps" to help prioritize compounds for clinical testing.

Hence, The National Institutes of Health (NIH) announced the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership in April 2020, to establish a coordinated research strategy for prioritizing and speeding the development of the most promising treatments and vaccines.

The United States is also found to be dominating the market, owing to the presence of established infrastructure and the presence of major public and private companies. The increased research and development funding that is taking place, coupled with the presence of a highly developed research infrastructure, is accelerating the growth of the preclinical imaging market in the United States.

Furthermore, the increasing number of clinical research organizations (CROs) and pharmaceutical companies are thereby increasing the adoption of in-vivo imaging systems in Preclinical research, which is further accelerating the growth of this market.

In addition, corporations are offering new products to diversify their product portfolio. Bruker, for example, announced the debut of the Ultima Investigator Plus in March 2022, the newest modular platform addition to the industry-leading Ultima range of multiphoton microscopes for deep tissue fluorescence imaging. Investigator Plus enhances scientists' capacity to image deep and see more within tough specimens with an extended field of view, optimized optics for two- and three-photon imaging, and an increased close-coupled collection path. In addition, organizations are advancing on new products to expand their product portfolio. Bruker, for example, revealed the unveiling of the Ultima Investigator Plus in March 2022, the newest flexible platform addition to the industry-ahead Ultima range of multiphoton microscopes for deep tissue fluorescence imaging. Researcher enhances scientists' ability to image deep and see more within specimens with an extended field of view, optimized optics for two and three-photon imaging, and an expanded close-coupled collection path.

Thus, all these factors have contributed to the growth of the market in the region.

Preclinical Imaging Market Competitor Analysis

The market studied is a moderately consolidated market owing to the various small and large market players. Some of the market players are Aspect Imaging Ltd, Bruker Corporation, Fujifilm Holdings Corporation, Li-Cor Biosciences, Mediso Ltd, Milabs BV, MR Solutions Ltd, PerkinElmer Inc., Euro-BioImaging ERIC, Trifoil Imaging, United Imaging Healthcare Co., Ltd., Photon etc., AXT PTY LTD, Advanced Molecular Vision, Inc., and IVIM Technology Corp. The players are adopting various strategies such as new product launches, and acquisition to remain competitive.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Technological Advancements in Molecular Imaging
    • 4.2.2 Increasing Demand for Non-invasive Small Animal Imaging Techniques
    • 4.2.3 Increase in Preclinical Research Funding, by Both Private and Public Organizations
  • 4.3 Market Restraints
    • 4.3.1 Strict Regulations in Preclinical Research
    • 4.3.2 High Installation and Operational Costs associated with Preclinical Imaging Modalities
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Modality
    • 5.1.1 Optical Imaging Systems
    • 5.1.2 Nuclear Imaging Systems
    • 5.1.3 Micro-MRI
    • 5.1.4 Micro-ultrasound
    • 5.1.5 Micro-CT
    • 5.1.6 Photoacoustic Imaging Systems
    • 5.1.7 Other Modality
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States
      • 5.2.1.2 Canada
      • 5.2.1.3 Mexico
    • 5.2.2 Europe
      • 5.2.2.1 Germany
      • 5.2.2.2 United Kingdom
      • 5.2.2.3 France
      • 5.2.2.4 Italy
      • 5.2.2.5 Spain
      • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia-Pacific
      • 5.2.3.1 China
      • 5.2.3.2 Japan
      • 5.2.3.3 India
      • 5.2.3.4 Australia
      • 5.2.3.5 South Korea
      • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Middle-East
      • 5.2.4.1 GCC
      • 5.2.4.2 South Africa
      • 5.2.4.3 Rest of Middle-East
    • 5.2.5 South America
      • 5.2.5.1 Brazil
      • 5.2.5.2 Argentina
      • 5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Aspect Imaging Ltd
    • 6.1.2 Bruker Corporation
    • 6.1.3 Fujifilm Holdings Corporation
    • 6.1.4 Mediso Ltd
    • 6.1.5 MR Solutions Ltd
    • 6.1.6 PerkinElmer Inc.
    • 6.1.7 Trifoil Imaging
    • 6.1.8 Euro-BioImaging ERIC
    • 6.1.9 United Imaging Healthcare Co. Ltd
    • 6.1.10 Photon etc.
    • 6.1.11 AXT PTY LTD
    • 6.1.12 Advanced Molecular Vision, Inc.
    • 6.1.13 IVIM Technology Corp.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS